nodes	percent_of_prediction	percent_of_DWPC	metapath
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	0.00184	0.00187	CcSEcCtD
Duloxetine—Pancreatitis—Methotrexate—muscle cancer	0.00184	0.00186	CcSEcCtD
Duloxetine—Discomfort—Etoposide—muscle cancer	0.00183	0.00186	CcSEcCtD
Duloxetine—Face oedema—Doxorubicin—muscle cancer	0.00181	0.00184	CcSEcCtD
Duloxetine—Hypersensitivity—Dactinomycin—muscle cancer	0.00181	0.00184	CcSEcCtD
Duloxetine—Abdominal discomfort—Methotrexate—muscle cancer	0.0018	0.00182	CcSEcCtD
Duloxetine—Gastrointestinal pain—Vincristine—muscle cancer	0.0018	0.00182	CcSEcCtD
Duloxetine—Confusional state—Etoposide—muscle cancer	0.00179	0.00182	CcSEcCtD
Duloxetine—Anaphylactic shock—Etoposide—muscle cancer	0.00178	0.0018	CcSEcCtD
Duloxetine—Mood swings—Doxorubicin—muscle cancer	0.00178	0.0018	CcSEcCtD
Duloxetine—Infection—Etoposide—muscle cancer	0.00177	0.00179	CcSEcCtD
Duloxetine—Ataxia—Doxorubicin—muscle cancer	0.00176	0.00179	CcSEcCtD
Duloxetine—Asthenia—Dactinomycin—muscle cancer	0.00176	0.00179	CcSEcCtD
Duloxetine—Blood creatinine increased—Doxorubicin—muscle cancer	0.00176	0.00178	CcSEcCtD
Duloxetine—Dysuria—Methotrexate—muscle cancer	0.00175	0.00178	CcSEcCtD
Duloxetine—Dehydration—Doxorubicin—muscle cancer	0.00175	0.00177	CcSEcCtD
Duloxetine—Thrombocytopenia—Etoposide—muscle cancer	0.00174	0.00177	CcSEcCtD
Duloxetine—Upper respiratory tract infection—Methotrexate—muscle cancer	0.00174	0.00177	CcSEcCtD
Duloxetine—Tachycardia—Etoposide—muscle cancer	0.00174	0.00176	CcSEcCtD
Duloxetine—Abdominal pain—Vincristine—muscle cancer	0.00174	0.00176	CcSEcCtD
Duloxetine—Body temperature increased—Vincristine—muscle cancer	0.00174	0.00176	CcSEcCtD
Duloxetine—Liver function test abnormal—Doxorubicin—muscle cancer	0.00173	0.00176	CcSEcCtD
Duloxetine—Skin disorder—Etoposide—muscle cancer	0.00173	0.00175	CcSEcCtD
Duloxetine—Erectile dysfunction—Methotrexate—muscle cancer	0.00173	0.00175	CcSEcCtD
Duloxetine—Hyperhidrosis—Etoposide—muscle cancer	0.00172	0.00174	CcSEcCtD
Duloxetine—Orthostatic hypotension—Doxorubicin—muscle cancer	0.00171	0.00174	CcSEcCtD
Duloxetine—Abdominal pain upper—Doxorubicin—muscle cancer	0.00171	0.00174	CcSEcCtD
Duloxetine—Photosensitivity reaction—Methotrexate—muscle cancer	0.00171	0.00173	CcSEcCtD
Duloxetine—Breast disorder—Doxorubicin—muscle cancer	0.0017	0.00172	CcSEcCtD
Duloxetine—Anorexia—Etoposide—muscle cancer	0.0017	0.00172	CcSEcCtD
Duloxetine—Aspartate aminotransferase increased—Doxorubicin—muscle cancer	0.00169	0.00171	CcSEcCtD
Duloxetine—Diarrhoea—Dactinomycin—muscle cancer	0.00168	0.00171	CcSEcCtD
Duloxetine—Nasopharyngitis—Doxorubicin—muscle cancer	0.00168	0.0017	CcSEcCtD
Duloxetine—Infestation NOS—Methotrexate—muscle cancer	0.00167	0.00169	CcSEcCtD
Duloxetine—Infestation—Methotrexate—muscle cancer	0.00167	0.00169	CcSEcCtD
Duloxetine—Gastritis—Doxorubicin—muscle cancer	0.00166	0.00168	CcSEcCtD
Duloxetine—Stevens-Johnson syndrome—Methotrexate—muscle cancer	0.00166	0.00168	CcSEcCtD
Duloxetine—Alanine aminotransferase increased—Doxorubicin—muscle cancer	0.00166	0.00168	CcSEcCtD
Duloxetine—Muscular weakness—Doxorubicin—muscle cancer	0.00166	0.00168	CcSEcCtD
Duloxetine—Renal failure—Methotrexate—muscle cancer	0.00164	0.00167	CcSEcCtD
Duloxetine—Stomatitis—Methotrexate—muscle cancer	0.00163	0.00165	CcSEcCtD
Duloxetine—NPY1R—renal system—muscle cancer	0.00163	0.114	CbGeAlD
Duloxetine—Conjunctivitis—Methotrexate—muscle cancer	0.00162	0.00165	CcSEcCtD
Duloxetine—Influenza—Doxorubicin—muscle cancer	0.00162	0.00165	CcSEcCtD
Duloxetine—Dysphagia—Doxorubicin—muscle cancer	0.00162	0.00165	CcSEcCtD
Duloxetine—Hypersensitivity—Vincristine—muscle cancer	0.00162	0.00164	CcSEcCtD
Duloxetine—Paraesthesia—Etoposide—muscle cancer	0.0016	0.00162	CcSEcCtD
Duloxetine—Pancreatitis—Doxorubicin—muscle cancer	0.00159	0.00161	CcSEcCtD
Duloxetine—Somnolence—Etoposide—muscle cancer	0.00158	0.0016	CcSEcCtD
Duloxetine—Hepatobiliary disease—Methotrexate—muscle cancer	0.00158	0.0016	CcSEcCtD
Duloxetine—Epistaxis—Methotrexate—muscle cancer	0.00158	0.0016	CcSEcCtD
Duloxetine—Asthenia—Vincristine—muscle cancer	0.00158	0.0016	CcSEcCtD
Duloxetine—Vomiting—Dactinomycin—muscle cancer	0.00156	0.00158	CcSEcCtD
Duloxetine—Rash—Dactinomycin—muscle cancer	0.00155	0.00157	CcSEcCtD
Duloxetine—Decreased appetite—Etoposide—muscle cancer	0.00155	0.00157	CcSEcCtD
Duloxetine—HTR2A—hindlimb—muscle cancer	0.00154	0.108	CbGeAlD
Duloxetine—Gastrointestinal disorder—Etoposide—muscle cancer	0.00154	0.00156	CcSEcCtD
Duloxetine—Fatigue—Etoposide—muscle cancer	0.00153	0.00156	CcSEcCtD
Duloxetine—Pain—Etoposide—muscle cancer	0.00152	0.00154	CcSEcCtD
Duloxetine—Constipation—Etoposide—muscle cancer	0.00152	0.00154	CcSEcCtD
Duloxetine—Dysuria—Doxorubicin—muscle cancer	0.00152	0.00154	CcSEcCtD
Duloxetine—Upper respiratory tract infection—Doxorubicin—muscle cancer	0.00151	0.00153	CcSEcCtD
Duloxetine—Haemoglobin—Methotrexate—muscle cancer	0.00151	0.00153	CcSEcCtD
Duloxetine—Diarrhoea—Vincristine—muscle cancer	0.0015	0.00152	CcSEcCtD
Duloxetine—Hepatitis—Methotrexate—muscle cancer	0.0015	0.00152	CcSEcCtD
Duloxetine—Haemorrhage—Methotrexate—muscle cancer	0.0015	0.00152	CcSEcCtD
Duloxetine—Pollakiuria—Doxorubicin—muscle cancer	0.0015	0.00152	CcSEcCtD
Duloxetine—Pharyngitis—Methotrexate—muscle cancer	0.00149	0.00151	CcSEcCtD
Duloxetine—Urinary tract disorder—Methotrexate—muscle cancer	0.00148	0.0015	CcSEcCtD
Duloxetine—Photosensitivity reaction—Doxorubicin—muscle cancer	0.00148	0.0015	CcSEcCtD
Duloxetine—Weight increased—Doxorubicin—muscle cancer	0.00148	0.0015	CcSEcCtD
Duloxetine—Urethral disorder—Methotrexate—muscle cancer	0.00147	0.00149	CcSEcCtD
Duloxetine—Weight decreased—Doxorubicin—muscle cancer	0.00147	0.00149	CcSEcCtD
Duloxetine—Feeling abnormal—Etoposide—muscle cancer	0.00147	0.00149	CcSEcCtD
Duloxetine—Hyperglycaemia—Doxorubicin—muscle cancer	0.00146	0.00148	CcSEcCtD
Duloxetine—Nausea—Dactinomycin—muscle cancer	0.00146	0.00148	CcSEcCtD
Duloxetine—Gastrointestinal pain—Etoposide—muscle cancer	0.00145	0.00148	CcSEcCtD
Duloxetine—Dizziness—Vincristine—muscle cancer	0.00145	0.00147	CcSEcCtD
Duloxetine—Infestation NOS—Doxorubicin—muscle cancer	0.00145	0.00147	CcSEcCtD
Duloxetine—Infestation—Doxorubicin—muscle cancer	0.00145	0.00147	CcSEcCtD
Duloxetine—Visual impairment—Methotrexate—muscle cancer	0.00144	0.00147	CcSEcCtD
Duloxetine—Stevens-Johnson syndrome—Doxorubicin—muscle cancer	0.00143	0.00145	CcSEcCtD
Duloxetine—Renal failure—Doxorubicin—muscle cancer	0.00142	0.00144	CcSEcCtD
Duloxetine—Erythema multiforme—Methotrexate—muscle cancer	0.00142	0.00144	CcSEcCtD
Duloxetine—Urticaria—Etoposide—muscle cancer	0.00141	0.00143	CcSEcCtD
Duloxetine—Jaundice—Doxorubicin—muscle cancer	0.00141	0.00143	CcSEcCtD
Duloxetine—Stomatitis—Doxorubicin—muscle cancer	0.00141	0.00143	CcSEcCtD
Duloxetine—Abdominal pain—Etoposide—muscle cancer	0.00141	0.00143	CcSEcCtD
Duloxetine—Body temperature increased—Etoposide—muscle cancer	0.00141	0.00143	CcSEcCtD
Duloxetine—Conjunctivitis—Doxorubicin—muscle cancer	0.00141	0.00143	CcSEcCtD
Duloxetine—Urinary tract infection—Doxorubicin—muscle cancer	0.00141	0.00143	CcSEcCtD
Duloxetine—Eye disorder—Methotrexate—muscle cancer	0.0014	0.00142	CcSEcCtD
Duloxetine—Tinnitus—Methotrexate—muscle cancer	0.0014	0.00142	CcSEcCtD
Duloxetine—Vomiting—Vincristine—muscle cancer	0.0014	0.00142	CcSEcCtD
Duloxetine—Cardiac disorder—Methotrexate—muscle cancer	0.00139	0.00141	CcSEcCtD
Duloxetine—Rash—Vincristine—muscle cancer	0.00138	0.0014	CcSEcCtD
Duloxetine—Dermatitis—Vincristine—muscle cancer	0.00138	0.0014	CcSEcCtD
Duloxetine—Headache—Vincristine—muscle cancer	0.00138	0.0014	CcSEcCtD
Duloxetine—Hepatobiliary disease—Doxorubicin—muscle cancer	0.00137	0.00139	CcSEcCtD
Duloxetine—Epistaxis—Doxorubicin—muscle cancer	0.00136	0.00138	CcSEcCtD
Duloxetine—Angiopathy—Methotrexate—muscle cancer	0.00136	0.00138	CcSEcCtD
Duloxetine—Immune system disorder—Methotrexate—muscle cancer	0.00135	0.00137	CcSEcCtD
Duloxetine—Mediastinal disorder—Methotrexate—muscle cancer	0.00135	0.00137	CcSEcCtD
Duloxetine—Chills—Methotrexate—muscle cancer	0.00135	0.00136	CcSEcCtD
Duloxetine—Alopecia—Methotrexate—muscle cancer	0.00132	0.00134	CcSEcCtD
Duloxetine—HTR2A—appendage—muscle cancer	0.00132	0.0928	CbGeAlD
Duloxetine—Mental disorder—Methotrexate—muscle cancer	0.00131	0.00133	CcSEcCtD
Duloxetine—Hypersensitivity—Etoposide—muscle cancer	0.00131	0.00133	CcSEcCtD
Duloxetine—Malnutrition—Methotrexate—muscle cancer	0.00131	0.00132	CcSEcCtD
Duloxetine—Erythema—Methotrexate—muscle cancer	0.00131	0.00132	CcSEcCtD
Duloxetine—Haemoglobin—Doxorubicin—muscle cancer	0.0013	0.00132	CcSEcCtD
Duloxetine—Nausea—Vincristine—muscle cancer	0.0013	0.00132	CcSEcCtD
Duloxetine—Haemorrhage—Doxorubicin—muscle cancer	0.0013	0.00132	CcSEcCtD
Duloxetine—Hepatitis—Doxorubicin—muscle cancer	0.0013	0.00132	CcSEcCtD
Duloxetine—Hypoaesthesia—Doxorubicin—muscle cancer	0.00129	0.00131	CcSEcCtD
Duloxetine—Pharyngitis—Doxorubicin—muscle cancer	0.00129	0.00131	CcSEcCtD
Duloxetine—Urinary tract disorder—Doxorubicin—muscle cancer	0.00128	0.0013	CcSEcCtD
Duloxetine—Oedema peripheral—Doxorubicin—muscle cancer	0.00128	0.0013	CcSEcCtD
Duloxetine—Dysgeusia—Methotrexate—muscle cancer	0.00128	0.0013	CcSEcCtD
Duloxetine—Asthenia—Etoposide—muscle cancer	0.00128	0.00129	CcSEcCtD
Duloxetine—Connective tissue disorder—Doxorubicin—muscle cancer	0.00128	0.00129	CcSEcCtD
Duloxetine—Urethral disorder—Doxorubicin—muscle cancer	0.00127	0.00129	CcSEcCtD
Duloxetine—Back pain—Methotrexate—muscle cancer	0.00126	0.00128	CcSEcCtD
Duloxetine—Pruritus—Etoposide—muscle cancer	0.00126	0.00128	CcSEcCtD
Duloxetine—Visual impairment—Doxorubicin—muscle cancer	0.00125	0.00127	CcSEcCtD
Duloxetine—Vision blurred—Methotrexate—muscle cancer	0.00123	0.00125	CcSEcCtD
Duloxetine—Erythema multiforme—Doxorubicin—muscle cancer	0.00123	0.00125	CcSEcCtD
Duloxetine—Diarrhoea—Etoposide—muscle cancer	0.00122	0.00123	CcSEcCtD
Duloxetine—Eye disorder—Doxorubicin—muscle cancer	0.00121	0.00123	CcSEcCtD
Duloxetine—Ill-defined disorder—Methotrexate—muscle cancer	0.00121	0.00123	CcSEcCtD
Duloxetine—Tinnitus—Doxorubicin—muscle cancer	0.00121	0.00123	CcSEcCtD
Duloxetine—Anaemia—Methotrexate—muscle cancer	0.00121	0.00122	CcSEcCtD
Duloxetine—Flushing—Doxorubicin—muscle cancer	0.0012	0.00122	CcSEcCtD
Duloxetine—Cardiac disorder—Doxorubicin—muscle cancer	0.0012	0.00122	CcSEcCtD
Duloxetine—Angiopathy—Doxorubicin—muscle cancer	0.00118	0.00119	CcSEcCtD
Duloxetine—NPY1R—vagina—muscle cancer	0.00118	0.0828	CbGeAlD
Duloxetine—Malaise—Methotrexate—muscle cancer	0.00118	0.00119	CcSEcCtD
Duloxetine—Dizziness—Etoposide—muscle cancer	0.00118	0.00119	CcSEcCtD
Duloxetine—Immune system disorder—Doxorubicin—muscle cancer	0.00117	0.00119	CcSEcCtD
Duloxetine—Vertigo—Methotrexate—muscle cancer	0.00117	0.00119	CcSEcCtD
Duloxetine—Mediastinal disorder—Doxorubicin—muscle cancer	0.00117	0.00119	CcSEcCtD
Duloxetine—Leukopenia—Methotrexate—muscle cancer	0.00117	0.00119	CcSEcCtD
Duloxetine—Chills—Doxorubicin—muscle cancer	0.00116	0.00118	CcSEcCtD
Duloxetine—Arrhythmia—Doxorubicin—muscle cancer	0.00116	0.00118	CcSEcCtD
Duloxetine—Alopecia—Doxorubicin—muscle cancer	0.00115	0.00116	CcSEcCtD
Duloxetine—Cough—Methotrexate—muscle cancer	0.00114	0.00116	CcSEcCtD
Duloxetine—Mental disorder—Doxorubicin—muscle cancer	0.00114	0.00115	CcSEcCtD
Duloxetine—Convulsion—Methotrexate—muscle cancer	0.00113	0.00115	CcSEcCtD
Duloxetine—Vomiting—Etoposide—muscle cancer	0.00113	0.00115	CcSEcCtD
Duloxetine—Erythema—Doxorubicin—muscle cancer	0.00113	0.00115	CcSEcCtD
Duloxetine—Malnutrition—Doxorubicin—muscle cancer	0.00113	0.00115	CcSEcCtD
Duloxetine—Rash—Etoposide—muscle cancer	0.00112	0.00114	CcSEcCtD
Duloxetine—Dermatitis—Etoposide—muscle cancer	0.00112	0.00114	CcSEcCtD
Duloxetine—Headache—Etoposide—muscle cancer	0.00111	0.00113	CcSEcCtD
Duloxetine—Flatulence—Doxorubicin—muscle cancer	0.00111	0.00113	CcSEcCtD
Duloxetine—Chest pain—Methotrexate—muscle cancer	0.00111	0.00113	CcSEcCtD
Duloxetine—Myalgia—Methotrexate—muscle cancer	0.00111	0.00113	CcSEcCtD
Duloxetine—Arthralgia—Methotrexate—muscle cancer	0.00111	0.00113	CcSEcCtD
Duloxetine—Tension—Doxorubicin—muscle cancer	0.00111	0.00113	CcSEcCtD
Duloxetine—Dysgeusia—Doxorubicin—muscle cancer	0.00111	0.00112	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	0.0011	0.00112	CcSEcCtD
Duloxetine—Discomfort—Methotrexate—muscle cancer	0.0011	0.00111	CcSEcCtD
Duloxetine—Nervousness—Doxorubicin—muscle cancer	0.0011	0.00111	CcSEcCtD
Duloxetine—Back pain—Doxorubicin—muscle cancer	0.00109	0.00111	CcSEcCtD
Duloxetine—NPY1R—head—muscle cancer	0.00109	0.0765	CbGeAlD
Duloxetine—Muscle spasms—Doxorubicin—muscle cancer	0.00109	0.0011	CcSEcCtD
Duloxetine—Confusional state—Methotrexate—muscle cancer	0.00107	0.00109	CcSEcCtD
Duloxetine—Anaphylactic shock—Methotrexate—muscle cancer	0.00107	0.00108	CcSEcCtD
Duloxetine—Vision blurred—Doxorubicin—muscle cancer	0.00107	0.00108	CcSEcCtD
Duloxetine—Infection—Methotrexate—muscle cancer	0.00106	0.00107	CcSEcCtD
Duloxetine—Nausea—Etoposide—muscle cancer	0.00106	0.00107	CcSEcCtD
Duloxetine—NPY1R—testis—muscle cancer	0.00105	0.0739	CbGeAlD
Duloxetine—Ill-defined disorder—Doxorubicin—muscle cancer	0.00105	0.00106	CcSEcCtD
Duloxetine—Nervous system disorder—Methotrexate—muscle cancer	0.00104	0.00106	CcSEcCtD
Duloxetine—Anaemia—Doxorubicin—muscle cancer	0.00104	0.00106	CcSEcCtD
Duloxetine—Thrombocytopenia—Methotrexate—muscle cancer	0.00104	0.00106	CcSEcCtD
Duloxetine—Agitation—Doxorubicin—muscle cancer	0.00104	0.00105	CcSEcCtD
Duloxetine—Skin disorder—Methotrexate—muscle cancer	0.00103	0.00105	CcSEcCtD
Duloxetine—Hyperhidrosis—Methotrexate—muscle cancer	0.00103	0.00104	CcSEcCtD
Duloxetine—Malaise—Doxorubicin—muscle cancer	0.00102	0.00103	CcSEcCtD
Duloxetine—Vertigo—Doxorubicin—muscle cancer	0.00102	0.00103	CcSEcCtD
Duloxetine—Anorexia—Methotrexate—muscle cancer	0.00102	0.00103	CcSEcCtD
Duloxetine—Syncope—Doxorubicin—muscle cancer	0.00101	0.00103	CcSEcCtD
Duloxetine—Leukopenia—Doxorubicin—muscle cancer	0.00101	0.00103	CcSEcCtD
Duloxetine—Palpitations—Doxorubicin—muscle cancer	0.000999	0.00101	CcSEcCtD
Duloxetine—Loss of consciousness—Doxorubicin—muscle cancer	0.000993	0.00101	CcSEcCtD
Duloxetine—Cough—Doxorubicin—muscle cancer	0.000986	0.001	CcSEcCtD
Duloxetine—Convulsion—Doxorubicin—muscle cancer	0.000979	0.000993	CcSEcCtD
Duloxetine—Hypertension—Doxorubicin—muscle cancer	0.000976	0.00099	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Methotrexate—muscle cancer	0.00097	0.000984	CcSEcCtD
Duloxetine—Insomnia—Methotrexate—muscle cancer	0.000963	0.000977	CcSEcCtD
Duloxetine—Arthralgia—Doxorubicin—muscle cancer	0.000962	0.000976	CcSEcCtD
Duloxetine—Myalgia—Doxorubicin—muscle cancer	0.000962	0.000976	CcSEcCtD
Duloxetine—Chest pain—Doxorubicin—muscle cancer	0.000962	0.000976	CcSEcCtD
Duloxetine—Anxiety—Doxorubicin—muscle cancer	0.000959	0.000973	CcSEcCtD
Duloxetine—Paraesthesia—Methotrexate—muscle cancer	0.000957	0.00097	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	0.000956	0.000969	CcSEcCtD
Duloxetine—Discomfort—Doxorubicin—muscle cancer	0.000951	0.000964	CcSEcCtD
Duloxetine—Somnolence—Methotrexate—muscle cancer	0.000947	0.000961	CcSEcCtD
Duloxetine—Dry mouth—Doxorubicin—muscle cancer	0.000941	0.000955	CcSEcCtD
Duloxetine—Dyspepsia—Methotrexate—muscle cancer	0.000938	0.000951	CcSEcCtD
Duloxetine—Confusional state—Doxorubicin—muscle cancer	0.00093	0.000943	CcSEcCtD
Duloxetine—Decreased appetite—Methotrexate—muscle cancer	0.000926	0.000939	CcSEcCtD
Duloxetine—Anaphylactic shock—Doxorubicin—muscle cancer	0.000922	0.000936	CcSEcCtD
Duloxetine—Oedema—Doxorubicin—muscle cancer	0.000922	0.000936	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Methotrexate—muscle cancer	0.00092	0.000933	CcSEcCtD
Duloxetine—Fatigue—Methotrexate—muscle cancer	0.000918	0.000932	CcSEcCtD
Duloxetine—Infection—Doxorubicin—muscle cancer	0.000916	0.00093	CcSEcCtD
Duloxetine—Pain—Methotrexate—muscle cancer	0.000911	0.000924	CcSEcCtD
Duloxetine—Shock—Doxorubicin—muscle cancer	0.000907	0.000921	CcSEcCtD
Duloxetine—Nervous system disorder—Doxorubicin—muscle cancer	0.000905	0.000918	CcSEcCtD
Duloxetine—Thrombocytopenia—Doxorubicin—muscle cancer	0.000903	0.000916	CcSEcCtD
Duloxetine—Tachycardia—Doxorubicin—muscle cancer	0.0009	0.000913	CcSEcCtD
Duloxetine—Skin disorder—Doxorubicin—muscle cancer	0.000896	0.000909	CcSEcCtD
Duloxetine—Hyperhidrosis—Doxorubicin—muscle cancer	0.000892	0.000905	CcSEcCtD
Duloxetine—Anorexia—Doxorubicin—muscle cancer	0.000879	0.000892	CcSEcCtD
Duloxetine—Feeling abnormal—Methotrexate—muscle cancer	0.000878	0.00089	CcSEcCtD
Duloxetine—Gastrointestinal pain—Methotrexate—muscle cancer	0.000871	0.000884	CcSEcCtD
Duloxetine—Urticaria—Methotrexate—muscle cancer	0.000846	0.000858	CcSEcCtD
Duloxetine—Abdominal pain—Methotrexate—muscle cancer	0.000842	0.000854	CcSEcCtD
Duloxetine—Body temperature increased—Methotrexate—muscle cancer	0.000842	0.000854	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Doxorubicin—muscle cancer	0.00084	0.000852	CcSEcCtD
Duloxetine—Insomnia—Doxorubicin—muscle cancer	0.000834	0.000846	CcSEcCtD
Duloxetine—Paraesthesia—Doxorubicin—muscle cancer	0.000828	0.00084	CcSEcCtD
Duloxetine—Somnolence—Doxorubicin—muscle cancer	0.00082	0.000832	CcSEcCtD
Duloxetine—Dyspepsia—Doxorubicin—muscle cancer	0.000812	0.000824	CcSEcCtD
Duloxetine—Decreased appetite—Doxorubicin—muscle cancer	0.000802	0.000813	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Doxorubicin—muscle cancer	0.000796	0.000808	CcSEcCtD
Duloxetine—Fatigue—Doxorubicin—muscle cancer	0.000795	0.000807	CcSEcCtD
Duloxetine—Pain—Doxorubicin—muscle cancer	0.000789	0.0008	CcSEcCtD
Duloxetine—Constipation—Doxorubicin—muscle cancer	0.000789	0.0008	CcSEcCtD
Duloxetine—Hypersensitivity—Methotrexate—muscle cancer	0.000785	0.000796	CcSEcCtD
Duloxetine—HTR6—head—muscle cancer	0.000765	0.0538	CbGeAlD
Duloxetine—Asthenia—Methotrexate—muscle cancer	0.000764	0.000775	CcSEcCtD
Duloxetine—Feeling abnormal—Doxorubicin—muscle cancer	0.00076	0.000771	CcSEcCtD
Duloxetine—Gastrointestinal pain—Doxorubicin—muscle cancer	0.000754	0.000765	CcSEcCtD
Duloxetine—Pruritus—Methotrexate—muscle cancer	0.000754	0.000765	CcSEcCtD
Duloxetine—Urticaria—Doxorubicin—muscle cancer	0.000733	0.000743	CcSEcCtD
Duloxetine—Abdominal pain—Doxorubicin—muscle cancer	0.000729	0.00074	CcSEcCtD
Duloxetine—Body temperature increased—Doxorubicin—muscle cancer	0.000729	0.00074	CcSEcCtD
Duloxetine—Diarrhoea—Methotrexate—muscle cancer	0.000729	0.000739	CcSEcCtD
Duloxetine—Dizziness—Methotrexate—muscle cancer	0.000704	0.000715	CcSEcCtD
Duloxetine—Hypersensitivity—Doxorubicin—muscle cancer	0.00068	0.000689	CcSEcCtD
Duloxetine—Vomiting—Methotrexate—muscle cancer	0.000677	0.000687	CcSEcCtD
Duloxetine—Rash—Methotrexate—muscle cancer	0.000672	0.000681	CcSEcCtD
Duloxetine—Dermatitis—Methotrexate—muscle cancer	0.000671	0.000681	CcSEcCtD
Duloxetine—Headache—Methotrexate—muscle cancer	0.000667	0.000677	CcSEcCtD
Duloxetine—Asthenia—Doxorubicin—muscle cancer	0.000662	0.000671	CcSEcCtD
Duloxetine—Pruritus—Doxorubicin—muscle cancer	0.000653	0.000662	CcSEcCtD
Duloxetine—Nausea—Methotrexate—muscle cancer	0.000633	0.000642	CcSEcCtD
Duloxetine—Diarrhoea—Doxorubicin—muscle cancer	0.000631	0.00064	CcSEcCtD
Duloxetine—Dizziness—Doxorubicin—muscle cancer	0.00061	0.000619	CcSEcCtD
Duloxetine—Vomiting—Doxorubicin—muscle cancer	0.000586	0.000595	CcSEcCtD
Duloxetine—Rash—Doxorubicin—muscle cancer	0.000582	0.00059	CcSEcCtD
Duloxetine—Dermatitis—Doxorubicin—muscle cancer	0.000581	0.000589	CcSEcCtD
Duloxetine—Headache—Doxorubicin—muscle cancer	0.000578	0.000586	CcSEcCtD
Duloxetine—Nausea—Doxorubicin—muscle cancer	0.000548	0.000556	CcSEcCtD
Duloxetine—SLC6A3—head—muscle cancer	0.000457	0.0322	CbGeAlD
Duloxetine—HTR2C—head—muscle cancer	0.000442	0.0311	CbGeAlD
Duloxetine—SLC6A3—testis—muscle cancer	0.000442	0.0311	CbGeAlD
Duloxetine—HTR2A—embryo—muscle cancer	0.000438	0.0308	CbGeAlD
Duloxetine—CYP1A2—renal system—muscle cancer	0.000424	0.0298	CbGeAlD
Duloxetine—SLC6A4—head—muscle cancer	0.000419	0.0295	CbGeAlD
Duloxetine—SLC6A2—head—muscle cancer	0.000369	0.026	CbGeAlD
Duloxetine—SLC6A2—testis—muscle cancer	0.000357	0.0251	CbGeAlD
Duloxetine—HTR2A—smooth muscle tissue—muscle cancer	0.000344	0.0242	CbGeAlD
Duloxetine—HTR2A—renal system—muscle cancer	0.000332	0.0233	CbGeAlD
Duloxetine—CYP2D6—renal system—muscle cancer	0.000302	0.0212	CbGeAlD
Duloxetine—HTR2A—tendon—muscle cancer	0.000259	0.0182	CbGeAlD
Duloxetine—HTR2A—vagina—muscle cancer	0.00024	0.0169	CbGeAlD
Duloxetine—HTR2A—head—muscle cancer	0.000222	0.0156	CbGeAlD
Duloxetine—HTR2A—testis—muscle cancer	0.000214	0.0151	CbGeAlD
Duloxetine—CYP2D6—head—muscle cancer	0.000202	0.0142	CbGeAlD
Duloxetine—CYP2D6—testis—muscle cancer	0.000195	0.0137	CbGeAlD
